AnaptysBio, Inc. (ANAB) is a Biotechnology company in the Healthcare sector, currently trading at $70.22. It has a SharesGrow Score of 50/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ANAB = $118.10 (+68.2% from the current price, the stock appears undervalued). Analyst consensus target is ANAB = $74 (+5% upside).
Valuation: ANAB trades at a trailing Price-to-Earnings (P/E) of -137.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 7.88.
Financials: revenue is $235M, +218.6%/yr average growth. Net income is $13M (loss), growing at +25%/yr. Net profit margin is -5.6% (negative). Gross margin is 99% (+21.7 pp trend).
Balance sheet: total debt is $14M against $37M equity (Debt-to-Equity (D/E) ratio 0.38, conservative). Current ratio is 9.07 (strong liquidity). Debt-to-assets is 3.9%. Total assets: $364M.
Analyst outlook: 15 / 21 analysts rate ANAB as buy (71%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 31/100 (Fail), Growth 100/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 70/100 (Pass), Future 73/100 (Pass), Income 10/100 (Fail).
